Clinical Research Training Scholarship in Neuromuscular Disease - American Academy of Neurology and American Brain Foundation 

GBS|CIDP Foundation International | 2019 Research Grant Opportunity
The GBS|CIDP Foundation International is pleased to announce a competition for 2019 Research Grants 

As part of the GBS|CIDP Foundation International’s mission to provide education and support research, we offer research grants to qualified applicants. Grants are made possible through the benevolence of many sources, including the Helen S. Manheimer Research Fund, contributions from individuals who have been personally touched by GBS or CIDP and by several commercial sources.

Through the generosity of these contributors, to whom the Foundation is most grateful, we are able to offer a Research Grant Program. The GBS|CIDP Foundation International has worldwide representation, sharing resources with local support group chapters nationally and internationally.

Foundation interests include GBS, both demyelinating and axonal variants, Miller Fisher syndrome, CIDP, multifocal motor neuropathy, and others. Research interests cover a broad range of subjects including development of methods to more rapidly diagnose these disorders, creation of educational and communication programs to inform patients and families of the Foundation’s availability, identification of mechanisms involved in the pathogenesis of family disorders, development of more effective treatments to limit the disease process, prevent complications and reduce long-term adverse sequelae.

Click here to view the process schedule. 
2019 GBS | CIDP International 2019 Grant Opportunity Announcement. 


  • The SPIN (Scientific Progress – Immunoglobulins in Neurology) Awards are part of the Grifols Scientific Awards program, which is committed to promoting scientific research as the cornerstone of a process that will lead to better health and quality of life for patients: 

GBS | CIDP Foundation

In March 2018 Congress passed an omnibus bill that finalized Fiscal Year 2018 appropriations. Guillain-Barré Syndrome was again listed as a condition eligible for study! Now is the time to begin applications for available grants, below is more detailed information regarding applications and possible awards.  Please share with your associates!

Congressionally Directed Topic Areas. All applications submitted to the PRMRP must address at least one of the FY18 PRMRP Congressionally directed topic areas.  The FY18 PRMRP Topic Areas are as follows:

  • Acute Lung Injury
  • Antimicrobial Resistance
  • Arthritis
  • Burn Pit Exposure
  • Cardiomyopathy
  • Cerebellar Ataxia
  • Chronic Migraine and Post-Traumatic Headache
  • Chronic Pain Management
  • Congenital Heart Disease
  • Constrictive Bronchiolitis
  • Diabetes
  • Dystonia
  • Eating Disorders
  • Emerging Infectious Diseases
  • Endometriosis
  • Epidermolysis Bullosa
  • Focal Segmental Glomerulosclerosis
  • Fragile X Syndrome
  • Guillain-Barré Syndrome
  • Hepatitis B and C
  • Hereditary Angioedema
  • Hydrocephalus
  • Immunomonitoring of Intestinal Transplants
  • Inflammatory Bowel Diseases
  • Interstitial Cystitis
  • Lung Injury
  • Malaria
  • Metals Toxicology
  • Mitochondrial Disease
  • Musculoskeletal Disorders
  • Myotonic Dystrophy
  • Non-Opioid Pain Management
  • Nutrition Optimization
  • Pancreatitis
  • Pathogen-Inactivated Blood Products
  • Post-Traumatic Osteoarthritis
  • Pressure Ulcers
  • Pulmonary Fibrosis
  • Respiratory Health
  • Rett Syndrome
  • Rheumatoid Arthritis
  • Scleroderma
  • Sleep Disorders
  • Spinal Muscular Atrophy
  • Sustained-Release Drug Delivery
  • Tinnitus
  • Tuberculosis
  • Vascular Malformations
  • Women’s Heart Disease


The mission of the PRMRP is to encourage, identify, and select military health-related research of exceptional scientific merit. Relevance to the healthcare needs of military Service members, Veterans, and their family members is a key feature of each FY18 PRMRP award mechanism.


Award Mechanism


Key Mechanism Elements


Clinical Trial Award

Assistant Professor level or above (or equivalent)

  • Preproposal submission is required; application submission is by invitation only.
  • Supports the rapid implementation of clinical trials of novel interventions with the potential to have a significant impact on patient care in the topic area(s) of interest.
  • Proposed projects may range from small proof-of-concept trials through large-scale, definitive trials.
  • Investigational New Drug or Investigational Device Exemption applications, if needed, should be submitted to the Food and Drug Administration by the PRMRP application submission deadline.
  • Funding limit not defined; requested funding must be appropriate for the scope of work proposed
  • Maximum period of performance is 4 years

Discovery Award

Postdoctoral fellow or clinical fellow (or equivalent) and above

  • Supports the exploration of a highly innovative new concept or untested theory.
  • Not intended to support the logical progression of an already established line of questioning.
  • Clinical trials will not be funded.
  • Reviewers will be blinded to the identity of the Principal Investigator (PI), collaborators, and their organization(s).
  • Maximum of $200,000 for direct costs (plus indirect costs)
  • Maximum period of performance is 18 months

Focused Program Award

Full Professor level or above (or equivalent)

  • Preproposal submission is required; application submission is by invitation only.
  • Supports a synergistic, multidisciplinary research program of at least four distinct but complementary projects addressing an overarching goal.
  • Projects should work together to answer critical questions, resolve differing hypotheses, and translate laboratory findings to clinical applications.
  • Projects may range from exploratory/hypothesis-developing through small-scale clinical trials that together will address the overarching goal/question.
  • Research team of highly qualified, multidisciplinary project leaders should be led by a PI with demonstrated success in directing large, focused projects.
  • Maximum of $10 million for total costs (includes direct and indirect costs)
  • Maximum period of performance is 4 years

Investigator-Initiated Research Award

Assistant Professor level or above (or equivalent)

  • Preproposal submission is required; application submission is by invitation only.
  • Supports research that will make an original and important contribution to the field of research or patient care in the topic area(s) of interest.
  • Partnering PI Option available.
  • Clinical trials will not be funded.
  • Maximum of $1.2 million for direct costs (plus indirect costs)
  • Maximum of $1.5 million for direct costs (plus indirect costs) for applications including a Partnering PI Option
  • Maximum period of performance is 3 years

Technology/ Therapeutic Development Award

Assistant Professor level or above (or equivalent)

  • Supports the translation of promising preclinical findings into clinical applications for prevention, detection, diagnosis, treatment, or quality of life.
  • Product-oriented (e.g., device, drug, clinical guidelines). The product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product.
  • Clinical trials will not be funded.
  • Preproposal submission is required; application submission is by invitation only.
  • Maximum of $3.0 million for direct costs (plus indirect costs)
  • Maximum period of performance is 3 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the website. The application package containing the required forms for each award mechanism will also be found on A listing of all CDMRP funding opportunities can be obtained on the website by performing a basic search using CFDA Number 12.420. 

Applications must be submitted through the federal government's single-entry portal, Submission deadlines are not available until the Program Announcements are released.

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at

For more information about the PRMRP or other CDMRP-administered programs, please visit the CDMRP website ( 

image widget
Facebook Twitter